Currently xBrane is engaged IN THE DEVELOPMENT OF THE FOLLOWING COMPLEX GENERICS

Microsphere
Process Development
Clinical Compliance
Market Authorization
Octreosphere (Sandostatin® LAR)
19% Complete
Spherotide (Decapeptyl®/Trelstar®/Pamorelin®)
50% Complete
Risperisphere (Risperdal Consta®)
19% Complete
Exenasphere (Bydureon®)
19% Complete
Leuprosphere (Lupron®)
19% Complete
Biosimilars
Xlucane (Lucentis®)
25% Complete
Xcimzane (Cimzia®)
19% Complete
Xoncane (Oncaspar®)
19% Complete

Decapeptyl, Trelstar, Pamorelin, RisperdalConsta, Bydureon, LupronDepot, Sandostatin, Lucentis, Cimzia and Oncaspar are registered trademarks of their respective owners.

TEAM UP WITH US?

Don’t hesitate to contact us. Please fill in the contact form and an Xbrane Executive will contact you.

Or contact directly:

For our Controlled Release Generics
Martin Åmark
+46 76-309 37 77
martin.amark@xbrane.com

For our Biosimilars
Siavash Bashiri
+46 73-434 36 19
siavash.bashiri@xbrane.com